Lexon ready to choose antibody for colon cancer test
This article was originally published in Clinica
Executive Summary
US cancer diagnostics start-up Lexon is preparing to choose the monoclonal antibody it will use in its enzyme-linked immunoassay (ELISA) blood test for the colon cancer marker ebaf. The Tulsa, Oklahoma-based company has narrowed its choice down to two candidates out of an original field of more than 30 antibodies.